Table 1.
Characteristics of Patients Who Received Interleukin-2 with or Without Active Specific Immunotherapy with Antigens from Autologous Proliferating Tumor Cells
| IL2 | IL2+ASI | |
|---|---|---|
| Total number of patients | 117 | 32 |
| Median age when received IL2 | 53 years | 46 years |
| Female | 56 (48%) | 12 (38%) |
| Regionally recurrent stage III | 11 (11%) | 8 (25%) |
| M1A | 12 (12%) | 8 (25%) |
| M1B | 13 (13%) | 2 (6%) |
| M1C | 61 63%) | 15 (44%) |
| Unknown stage | 20 (17%) | 0 |
Lactic dehydrogenase levels were not used to modify stage.
IL2, interleukin-2; ASI, active specific immunotherapy; M1A, distant lymph node and/or soft tissue metastases; M1B, lung metastases with or without soft tissue metastases; M1C, visceral metastases.